Healthways Inc. (NASDAQ: HWAY) could be named “The Implosion Stock of the Day.” Revenues rose 3.3% from a year earlier to $176.2 million, but that sequential earnings gain is actually more than a 6% annual…
Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work for less than it can. Novartis will take a restructuring charge of $300 million.…
Monday is called “Merger Monday” for a reason and this morning is a classic example of its namesake. We have seen multiple deals and news outstanding on pending deals. We recently noted that far…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit hard by…
We have compiled a detailed list of expected upside in the biotech sector. The sector has consolidated and now there is about to be a rush of earnings reports from tomorrow’s emerging drug companies. …
Drug and medical stocks are not generally thought of as stocks hitting 52-week highs by the investing public. So what about when a company decides to unlock shareholder value by breaking itself up? Abbott…
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more competition…
Boeing Co. (NYSE: BA) doesn’t have enough trouble, what with three-year delays to its new passenger liner and an order cancellation for its newest freight hauler just days before the new plane was set…
2011 has not exactly turned out the way many market pundits expected at the start of the year. The economy has slowed down to near-recession levels, the flight to safety has bond yields down…
Medical device maker Boston Scientific Corp. (NYSE: BSX) has named a new president who will take over on October 17th and who will then be elevated to CEO on November 1, 2012. Was Boston…
A new heart drug aimed a reducing the risk of strokes has outperformed the current drug of choice, warfarin, in a study that shows it lowers risk from a type of arrhythmia by 21%…
VIVUS, Inc. (NASDAQ: VVUS) is in the news this morning after entering into an agreements with a select group of institutional investors to sell 6,889,098 shares of its common stock. Rather than this being…
There is an old rule of thumb from biotech investors and traders… SELL FDA APPROVALS. This is very counter-intuitive on the surface but we wanted to explain in more detail why this is the…
Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for prostate cancer. The limited life-extension versus a high cost for the treatment is apparently…
Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning. The results of both drug behemoths are largely in line with analysts estimates and with…